What is Skyhawk Therapeutics?
Founded in 2015 and headquartered in Massachusetts, Skyhawk Therapeutics operates at the intersection of computational biology and medicinal chemistry. The company specializes in the development of small molecule therapeutics designed to correct RNA expression, a novel approach that addresses the root causes of complex diseases. By focusing on RNA-splicing modulation, Skyhawk aims to unlock therapeutic targets previously considered undruggable, thereby expanding the horizon for pharmaceutical intervention in oncology, neurology, and rare genetic disorders.
How much funding has Skyhawk Therapeutics raised?
Skyhawk Therapeutics has raised a total of $133M across 1 funding round:
Unspecified
$133M
Unspecified (2021): $133M with participation from Fidelity
Key Investors in Skyhawk Therapeutics
Fidelity
Fidelity Investments is a global financial services firm providing comprehensive wealth management, brokerage, and institutional advisory solutions, often acting as a cornerstone investor in high-growth biotechnology and life sciences ventures.
What's next for Skyhawk Therapeutics?
With the recent influx of capital, Skyhawk Therapeutics is poised to accelerate its clinical-stage research and expand its internal pipeline. The strategic focus will likely shift toward scaling its proprietary SkySTAR platform to identify new therapeutic candidates while strengthening its collaborative partnerships with major pharmaceutical entities. As the company transitions into more advanced development phases, the focus remains on validating its RNA-targeting small molecules in human trials, which will be critical for long-term commercial viability and market leadership in the biotech landscape.
See full Skyhawk Therapeutics company page
